About: SPC manufacturing waiver

Health 28-06-2019

New pharma boss: Next EU Commission should be clear on how to protect innovation

The next EU Commission should take a stronger position on innovation in the pharma sector, the new leader of the European Federation of Pharmaceutical Industries and Associations (EFPIA) told EURACTIV.com in an interview.
Health 29-01-2019

Pharma industry raises the alarm about stockpiling of generic drugs

The industry of innovative medicines is concerned with a recent vote in the European Parliament on the stockpiling of generic drugs, saying that it causes uncertainty over innovation in the pharmaceutical field.
Health 21-01-2019

Discussion heats up over stockpiling of generic drugs under patent protection

The Commission has announced its intention to add a manufacturing waiver to supplementary protection certificates (SPC), as part of its upgraded 2015 Single Market Strategy.
Health 30-11-2018

The European Commission should shelve its patent law proposal

The European Commission is considering an initiative that would permanently hobble the continent's economy, writes Jan Fischer.
Health 29-11-2018

Protecting the spark, avoiding the storm

Every new treatment, every transformational shift in the outlook for patients starts with the spark of an idea, writes Nathalie Moll.
Health 23-10-2018

EU generics industry slams US ‘intervention’ in SPC manufacturing waiver talks

The EU generics industry has accused the US government of intervening in the ongoing discussion in the EU on the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver.
Health 03-07-2018

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  
Health 12-06-2018

Andriukaitis: SPC manufacturing waiver does not damage pharma innovation

The European Commission’s proposal to add an SPC manufacturing waiver on exports will not damage innovation, as the pharma industry claims, and only intends to support small and medium generic drug companies, according to EU Health Commissioner Vytenis Andriukaitis.
Health 07-05-2018

Pharma boss: Incentives based on outcomes will optimise EU healthcare

An outcomes-based approach for incentives in the pharmaceutical sector would help optimise the entire healthcare systems, Nathalie Moll told EURACTIV.com in an interview.
Health 30-03-2018

Generic industry boss: SPC manufacturing waiver won’t harm originators’ innovation

The generic industry’s request for an SPC (supplementary protection certificates)  manufacturing waiver, which would allow them to produce in the EU SPC-protected drugs for other markets, does not influence or harm innovators’ rights, Marc–Alexander Mahl told EURACTIV.com in an interview. He...
Health 29-01-2018

Health expert: Europe should not put its dominant pharma innovation at risk

The European Union should not create an environment more favourable to generics compared to the innovative pharmaceuticals, as it risks weakening Europe’s overall global strength in pharmaceuticals and in research, Professor Adrian Towse told EURACTIV.com in an interview.

Want to know what's going on in the EU Capitals daily? Subscribe now to our new 9am newsletter.